Home

JUDITH SEGALL

CIK 1054745 · Director of Admin & Secretary · last filed 2021-06-08

JUDITH SEGALL is a Director of Admin & Secretary who has filed 13 SEC Form 4 insider transactions across 3 companies since 2009. The most recent filing, for AGE, was dated Jun 8, 2021. Across all open-market trades the lifetime net is −$313.8K, making them a net seller over the disclosed history. 32 SEC filings were submitted jointly with Lineage Cell Therapeutics, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

13

Lifetime Open-Market Net

-$313.8K

Filer Profile

Reported Address
1010 ATLANTIC AVENUE
SUITE 102
ALAMEDA, CA 94501
Related Filers
Lineage Cell Therapeutics, Inc. — 32 joint filings, latest 2017-02-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Serina Therapeutics, Inc. (AGE) Delisted Director of Admin & Secretary — $11.10 — $0 2 2021-06-08
Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Vice President & Secretary 594,645 — — -$313.8K 10 2016-03-04
Asterias Biotherapeutics, Inc. (AST) Delisted Corporate Secretary — — — $0 1 2015-02-18

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2021-06-08 Serina Therapeutics, Inc. (AGE) Delisted Grant (A) — $0 EDGAR
2019-11-21 Serina Therapeutics, Inc. (AGE) Delisted Grant (A) — $0 EDGAR
2016-03-04 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Grant (A) — $0 EDGAR
2015-03-05 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Grant (A) — $0 EDGAR
2015-02-18 Asterias Biotherapeutics, Inc. (AST) Delisted Grant (A) — $0 EDGAR
2014-03-24 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) — $0 EDGAR
2013-02-22 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Other (J) — $0 EDGAR
2011-11-25 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Mixed +74,230 $731 EDGAR
2010-11-23 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Sell (S) −27,128 -$204.1K EDGAR
2010-11-09 Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted Mixed +84,875 $21 EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.